UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASINGTON, D.C. 20549
FORM 10-KSB
[x] Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 For the Fiscal Year Ended December 31, 1999
-----------------
Commission File No. 0-109659
CITA BIOMEDICAL, INC.
COLORADO 93-0962072
- ------------------------------- -----------------
(State or other jurisdiction of (I.R.S. Employer
Incorporation or organization) Identification No.)
9025 Wilshire Blvd. Suite 301, Beverly Hills, CA 90211
------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number: (310) 550-4965
--------------
Securities registered under Section 12(b) of the Exchange Act: None
Securities registered under Section 12(g) of the Exchange Act:
$.0l Par Value Common Stock
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes _____ No__X__
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B contained in this form, and no disclosure will be contained, to
the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part M of this Form 10-KSB or any
amendment to this Form 10-KSB: [X]
Issuer's revenues for the most recent fiscal year: $505,455
The aggregate market value of the voting stock held by non-affiliates of the
issuer was approximately $1,911,666.42. The aggregate market value was based
upon the mean between the closing bid and asked price for the shares of common
stock as reported by the National Association of Securities Dealers, Inc. as of
December 31, 1999.
Number of shares outstanding of each of the issuer's classes of common equity,
as of December 31 1999: 7,766,662 shares of common stock and 1000 shares of
preferred stock.
DOCUMENTS INCORPORATED BY REFERENCE: See Exhibits.
Transitional Small Business Disclosure Format: Yes ____ No _X_
<PAGE>
PART I
ITEM 1. DESCRIPTION OF BUSINESS
A) General
CITA Biomedical, Inc. (the "Company"), was incorporated in Colorado on
June 9, 1981, under the name "Blue Grass Breeders, Inc." The Company was formed
for the purpose of engaging in the business of acquiring, breeding, racing and
selling thoroughbred horses. The Company completed an initial public offering of
its $.0l par value common shares in February 1983, receiving net proceeds of
approximately $2,134,000.
In March, 1987, the Company acquired all of the assets of Equine
Enterprises, Inc. a privately-held New Mexico corporation engaged in the
acquisition, breeding, racing and sale of thoroughbreds and quarterhorses. As a
result of the acquisition, the principal owners of Equine obtained control of
the Company. Until May 1, 1989, the Company continued in the business of
breeding and selling thoroughbred and quarterhorse broodmares and their
offspring.
On December 15, 1997 a special meeting of the shareholders of the
Company was held at which Joseph Dunn and Michael Hinton were elected to serve
as Directors of the Company. On August 12, 1998 the Company purchased CITA
Americas, Inc., (a Nevada Corporation), from Aviation Industries for 2.2 million
dollars in convertible preferred shares with a purchase price adjustment
provision at the end of twelve months whereby the purchase price maybe
recalculated down depending on the results of the final audit. It is anticipated
that such an adjustment will be made. Shortly thereafter, the Company changed
its name to CITA Biomedical, Inc.
CITA Americas, Inc. operates as a wholly owned subsidiary of CITA
Biomedical and is in the business ofthe treatment and rapid detoxification of
persons addicted to opiate based drugs whether natural or synthetic (e.g.,
Methadone, Heroin, Codeine, Demerol, Tylenol, Percasat, etc.)
The Company currently has contracts for detoxification with the
University of Illinois Chicago Medical Center, Centinela Hospital in Los
Angeles, and Sunset Speciality Hospital, Denver, Woodland Park Hospital,
Portland, OR, John C. Lincoln Hospital, Phoenix. The Company anticipates opening
new facilities in the coming year.
B) Narrative Description of Business
Employees and Consultants
The Company currently has eight full time paid employees and
two independent contractors. None of its employees have employment agreements.
Products
The current primary product that the Company offers is (UROD), Ultra
Rapid Opiate Detoxification. This revolutionary new and non-experimental,
procedure offers successful detoxification from heroin, methadone or other
opiate based prescription drugs to those individuals addicted without the
typical elongated painful withdrawal discomfort. Patients are successfully
detoxified in 4 - 6 hours with a hospital stay of 24 hours in most cases.
Patients are put under anesthesia and are given FDA approved opiate antagonist
drugs, which displaces the opiates at the receptor level. The UROD procedure
helps to reset the natural state of the body receptors.
<PAGE>
The Market
The opiate detoxification market is growing at a rapid rate. Opiate
addiction affects 0.7% of adult Americans sometime during their lifetime1. The
market for detoxification services amounted to approximately $10.5 billion in
the U.S. alone in 1998. This represented a 6% growth over the prior two years2.
Heroin and opiate addiction is currently at an epidemic state both nationally as
well as internationally. Between 1988 and 1995 according to National Institute
in Drug Addiction (NIDA), American users spent between $9 billion and $18
billion yearly. Recent studies estimate that there are almost two million heroin
users in the U.S3, and indications show the number is rising. Worldwide
estimates are significantly greater. More importantly, and likely greater, is a
large population of prescription opiate abusers has yet to be quantified by
researchers. Additionally, there are over 180,000 registered methadone addicts
in the U.S4. There are an estimated 1.5 million opiate addicts in the U.S. with
only 600,000 treatment slots currently available. In New York state alone, where
almost 30,000 such detoxifications are done each year5 and an additional 40,000
methadone patients are addicted, the state spends almost $140 million a year on
maintaining methadone addicts and $130 million for additional opiate
detoxifications6
Competition
The company considers it has two distinct competitors: i) traditional,
or longer, in-patient methods of detoxification, and (ii) methadone maintenance
or methadone taper detoxification
A. Traditional Methods of Detoxification
Traditional forms of detoxification are generally conducted in an
in-patient setting, in a hospital facility. Examples of such treatment centers
include the following:
1. Hazelden Foundation: A 28 day program, and costs approximately $23,000.
2. The Betty Ford Center: $20,000.00.
3. Cornerstone in New York: A 7-day detoxification treatment (not a program),
totaling approximately $4,000, with no outpatient follow up. (This is the
most typical form of conventional detoxification treatment). Aftercare is
billed separately, totaling approximately $7,000.
4. National Recovery Institute: A 14-28 day program costing approximately
$250 per day (average total cost $5,000). This program uses group therapy
and medication, including methadone. No follow up care included in cost
after detoxification is complete.
5. Methadone Maintenance: $4000.00 - $8000.00 per year with patient still
addicted.
- ---------------
1 Robbins LN, Regier DA (eds): Psychiatric Disorders in America. New York,
Free Press, 1991
2 National Institute on Drug Abuse: National Household Survey on Drug Abuse.
Washington DC, US Government Printing Office, 1998
3 American Psychiatric Association: Practice Guidelines for Treatment of
Patients With Substance Abuse Disorders: Alcohol, Cocaine, Opiods.
Washington DC American Psychiatric Association, 1995
4 National Institute on Drug Abuse: Washington DC
5 New York State Department of Social Services. DHLTC FFY 1995, Longitudinal
Inpatient (E) 807D Report
6 Rettig RA, Yarmolinski J (eds): Federal Regulations of Methadone Treatment.
Washington D.C., National Academy Press; New York State Department
of Services, Longitudinal Inpatient (E) 807D Report
<PAGE>
Most centers for treatment of opiate addiction refer the patients out
to a local hospital to do the detoxification portion of the treatment, then
bring the patient into an outpatient rehabilitation program. These hospital
detoxifications generally cost between $4,500 and $13,000, depending on daily
hospital rates, length of stay, any additional substances, etc. The main
advantage these programs have over CITA is they are generally covered by third
party payors, such as insurance companies and managed care entities. However,
this may change in the very near future, as CITA has recently been granted
reimbursement for treatment by some private insurance companies, as well as a
couple other third party, managed care groups (e.g., Creative Care Management,
Chicago, Illinois).
In terms of quality and strength, CITA has several distinct advantages over the
conventional methods of competition, including the following:
o Success rates - traditional forms of detoxification currently have a
documented 7-17% average success rate; CITA consistently enjoys a
documented 60% average success rate1.
o The usual 6-28 days for detoxification is reduced to just 6-8 hours.
o UROD is a guaranteed and 100% effective detoxification: all traces of
opiates are removed.
o Trained and board-certified UROD anesthesiologists oversee and monitor the
entire detoxification process, offering an even more controlled and safer
environment than conventional centers.
o No painful withdrawal symptoms are experienced while under anesthesia.
o Hospital stay is reduced to 23 to 36 hours: UROD frees hospital space for
more efficient use of the facilities.
o No traumatic transition experienced between detoxification and
rehabilitative treatment, thereby increasing the chances the patient will
continue to go on to further therapy and rehabilitation.
o UROD allows for an earlier return to work and home.
o No addictive medications are used as opiate substitutions.
o UROD accelerates repair of the body's cells and increases regeneration of
the natural opiates.
o The CITA Method reduces insurance requests for re-treatment.
o The CITA Method is the only viable treatment for methadone addicts.
o Based upon CITA's depth of experience (4,500 plus patients worldwide) and
one full year of operation in the US, CITA is now able to profitably assess
and target managed care and capitated populations.
- --------------
1 Rabinowitx J, Cohen H, Kotler M: One Year Outcomes of Ultra Rapid Opiate
Detoxification Combined with Naltrexone Maintinance. Journal of Drug
Abuse,1996
<PAGE>
B. Methadone
Developed in Germany around World War II, methadone was brought into
use in the United States in the mid 1960's as a method of treating those
addicted to heroin and other illegal substances. It was endorsed by the
government as a daily maintenance dose of synthetic opiates to produce a
pharmacological cross-tolerance, or "blockade," so that patients would not feel
any narcotic or euphoric effects if they were to self-administer a normal dose
of a short acting narcotic (e.g., heroin).
Methadone's intended use was four fold: 1) to counter the problem of
addicts' highs and lows (severe sickness and mood swings), allowing this
population to go back to work and normal daily functions; 2) to control issues
surrounding disease transmission through needle use (HIV); 3) to reduce criminal
activity related to obtaining the substance; and 4) to contribute to the
reduction of illegal drug trafficking.
Methadone's intended goal was to safely taper addicts off of opiates,
such as heroin, in a controlled environment, while offering counseling and
support on the psychological end. The problem with methadone has become apparent
in the increasing number of patients on the roles, the increasing amounts per
dosage that the patients are receiving, and the increasing number of methadone
facilities. Many patients report that their guidance counselors at the clinics
have no intention of weaning the patients off of the pharmaceutical, and rarely
offer counseling or help to get them detoxified.
Methadone clinics have become a place the patient visits each and every
morning, stands in line, pays their fees, takes their dose, and goes on with
their day. There is little attempt at helping the patients overcome the
addiction or work on other areas of their lives, and the clinics have no
economic incentive to begin reducing memberships. It has become a prison for
many, as they are told that there is no other solution. And, American taxpayers
are finished with supporting clinics that exacerbate the very problem they were
set up to solve.
The CITA Method of detoxification is that solution, and CITA argues
that it is the only method in existence today for the proper treatment of the
methadone population. CITA's research shows that approximately 70% of the
addicts receiving methadone maintenance are a treatable population, capable of
leading a normal and functional lifestyle. Thus, CITA is prepared to treat these
individuals.
C. Other Rapid Detoxification Programs
Although there are a few other small and little known clinics, small
hospitals and sole practitioners performing one form or another of one-day
detoxification, their impact is not deemed significant for several reasons
outlined below. The individual hospitals (CITA has identified three) that
provide this treatment do so at the $6,000 - $10,000 price range, and have done
such a small number of patients that CITA does not believe they will be able to
continue operations much longer. These hospitals have no opportunity for
regional or national reach, and have no capabilities of absorbing any of CITA's
prospective patients or market share due to CITA's own name branding.
<PAGE>
The small clinics and individual doctors that compete in the one-day
opiate detoxification market charge competitive prices in the upper $4000 to
lower $6000 price range and are based in free-standing, and often times
dangerous, clinic settings, with no regional or national reach.
CITA is aware of one doctor in New Jersey charging $4,000 for a
straight detoxification with no aftercare. It should be noted that the doctor
performs the procedure without a properly qualified anesthesiologist and in an
office setting - and has suffered severe criticism from professionals as a
result. In addition, the State of New Jersey is currently reviewing the doctor's
practices. There is also one center in Connecticut, which charges approximately
the same. Neither program includes aftercare counseling sessions, naltrexone
medication, or the initial lab work for the physical examination and medical
clearance. In addition, the literature on both of the programs is scarce,
general, and based on CITA's verbiage and procedure.
The only strength of these smaller competitors is the ability to charge
low rates due to their low overhead. The weakness in this business model is
twofold: one, there must be a jeopardy in safety standards and quality,
especially in the failure to use appropriate and board certified medical
personnel; and two, most of the individuals are not positioned as preferred
providers or as Medicaid providers. CITA's advantage by partnering with
established medical centers, will allow to maintain the hospital safety and
credibility: precisely positioning CITA for third party reimbursement.
In terms of quality and strength, CITA has several distinct advantages
over the other rapid detoxification centers, including the following:
o The CITA Method, combining rapid detoxification with a long-term aftercare
program for relapse prevention is the original method upon which all other
protocols are based:
o CITA has the only method of rapid detox that is affiliated with major
hospitals throughout the United States and world wide: CITA is the leader
in detoxification and rehabilitation.
o CITA's method of rapid detox is the only method that is clinically proven
to be safe and effective - based on over a decade of research - and is the
only one continually engaged in ongoing safety and improvement studies
through CITA's Scientific and Medical Advisory Committee.
o CITA's Ultra Rapid Opiate Detoxification has been successful on over 4,000
patients world wide, and is the only such method with no mortality,
morbidity or insurance claims.
o CITA offers the only rapid detoxification associated with the CITA
Foundation: an organization dedicated to quality assurance, community
outreach, education, charity events, research, development and humanitarian
endeavors.
o The CITA Method of treating opiate dependency is the only method that
combines and includes rapid detoxification with a tried and tested
aftercare therapy and relapse prevention protocol.
o CITA is the only organization dedicated to rapid detoxification with a
1-800 "Hotline" for emergencies, information, or simply to speak with a
counselor - 24 hours a day, 7 days a week.
<PAGE>
Conventional Detoxification and Aftercare
One of the serious limitations of conventional detoxification is that
many patients do not complete it. In single center studies, dropout rates have
been as high as 80% for outpatient detoxification2 and between 15% to 30% for
inpatient detoxification3. Multi-center studies report inpatient dropout rates
without distinguishing between opiates and other substances4. In the CATOR
(Comprehensive Assessment and Treatment Outcome Research) study, based on six
thousand patients from 19 treatment centers in 13 states, the dropout rates for
all inpatient substance abuse programs was 16% 5. In perhaps the only national
study reporting dropout rates from detoxification and treatment, which was
conducted in Israel, almost half of the patients abandoned inpatient
detoxification during the first week of the standard 30-day stay6. In New York
State, 26% of Medicaid clients dropout of inpatient detoxification7. This
amounts to an expenditure of almost $30 million per year for drop outs in New
York State alone. Under the CITA Method, due to the use of general anesthesia,
patients do not drop out during detoxification.
Another limitation of conventional detoxification is that many patients
are aversive to detoxification. Milby, for example, found that 34% of methadone
maintenance patients do not detoxify due to detoxification phobia. Thus, another
possible advantage of anesthesia aided detoxification is that it may facilitate
the detoxification of addicted persons who are afraid to approach conventional
detoxification.
Long-term results
It is well recognized that while detoxification is an important first
step, relapse prevention requires an aftercare program. The Drug Abuse Reporting
Program (DARP), a national treatment outcome study conducted in the United
States on several thousand patients from 52 different substance abuse programs,
found that 75% to 85% of patients treated in detoxification-only programs
relapsed within one year. As noted previously, completing detoxification is a
barrier to treatment for many patients. Of those patients who completed
conventional detoxification without dropping out and who subsequently entered an
aftercare program, at least half, to as many as 80% of them, returned to routine
use of opiates within the first year. For example, in the DARP study, relapse
rates for patients in after care programs ranged from 60% to 75% during the
first year. Another major national study of treatment outcomes, TOPS (Treatment
Outcome Prospective Study), found that of 2,280 select clients, who had
successfully completed detoxification and then enrolled and started after care
treatment, 57.2% had relapsed during the first year.
- ---------------
2 Stark M: Dropping Out of Substance Abuse Treatment: A Clinically Oriented
Review. Clin Psychol Rev 1992; 12:93-116.
3 Gossop M, Green L, Phillips G, Bradley B: Lapse, Relapse, and Survival Among
Opiate Addicts After Treatment: A perspective
follow-up study. Br J Psychiatry 1989; 154:348-353.
4 Stark M: Droping Out of Substrance Abuse Treatment: A Clinically Oriented
Review. Clin. Psychol. Rev 1992; 12:93-116.
5 Harrison PA, Hoffman NG, Steed SG. Drug and Alcohol Addiction Treatment
Outcome. In: Miller NS, ed. Comprehensive Handbook on Drug and Alcohol
Addiction. New York, 1991 Maecel Dekker Inc. 1163 - 1197
6 Levinson D: Comparisons of Outcomes Among Graduates of Various Detoxification
Programs. Jerusalem IL, State of Israel Ministry of Health, 1993.
7 In 1995 Medicaid paid for 28,921 detoxifications in New York State. In 7,474
cases patients left against medical advice after an average of 4.4 days.
Since detoxification takes 7 days and these patients left against medical
advice, they apparently dropped-out prior to completing detoxification.
<PAGE>
Methadone Treatment
According to Federal guidelines, while the eventual goal of methadone
programs is abstinence, for many patients, it is recognized that some patients
may need long-term methadone treatment. In practice, most programs encourage
long-term methadone maintenance and do not encourage detoxification 8. Not
surprisingly, it is rare to find patients who have successfully detoxified from
methadone without relapsing to opiate use9 In the TOPS study, which included
almost 2,700 methadone maintenance patients, by 13 weeks, 32% of patients had
dropped out of treatment, by 26 weeks 48%. Only 34% of patients remained in
methadone program for over one year. Similar results were obtained in the DARPS
study 10.
Thus, as compared to conventional detoxification, methadone appears to
have a higher dropout rate. After taking into account the higher drop out rate
and the dollars spent it is evident that the CITA UROD Method(TM) is far more
effective and cost efficient than methadone treatment.
CITA UROD Method(TM)
After adjusting for dropout rates during detoxification or methadone
treatment, the literature reviewed above suggests that of all patients who enter
opiate detoxification or methadone treatment, less than 30% are opiate free a
year later. In contrast to the relapse rates of patients treated with
conventional methods, a study of patients treated with the CITA UROD Method(TM)
found that after 1.5 years following UROD Procedure, 57% of 113 randomly
selected patients remained drug-free11. Despite the fact that the UROD study
allowed more time for relapse (1.5 years vs. 1 year), the results are
considerably better than most other studies. After controlling for dropout
(15%-50% of conventional inpatient detoxification patients), the success rate of
the CITA UROD Method(TM) in this study appears to be double that of conventional
detoxification and rehabilitation.
- -------------
8 Hubbard RL, Mardsen ME, Rachel JV, Harwood HJ, Cavenaugh ER, Ginzburg HM:
Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill,
NC, The University of North Carolina Press, 1989
9 Kleber HD: Detoxification From Methadone Maintenance; The State of the Art.
International Journal of Addiction 1977; 12:807-820
10 Hubbard RL, Mardsen ME, Rachel JV, Harwood HJ, Cavenaugh ER, Ginzburg HM:
Drug Abuse Treatment: A National Study of Effectiveness. Chapel
Hill, NC, The University of North Carolina Press, 1989
11 Rabinowitx J, Cohen H, Kotler M: One Year Outcomes of Ultra Rapid Opiate
Detoxification Combined with Naltrexone Maintinance. Journal of Drug
Abuse,1996
<PAGE>
Advertising and Promotion
CITA recognizes that the key to continued success and growth at this
time requires extensive promotion. This must be done aggressively and on a
nationwide scale. Responses and success rates based on patients treated indicate
that the CITA Method for detoxification and rehabilitation has earned itself an
excellent reputation among both the addicted population and substance abuse
professionals. CITA fully intends to continue this trend as demand for such
treatment increases. Relationships with third party payers, hospitals and
community leaders are equally as important as traditional forms of advertising
to aid in reaching CITA's goal to maintain the status of the standard of care in
opiate detoxification and rehabilitation.
CITA's strategy is to enhance, promote and support the fact that our service is
second to none, as we continue to corner the market in the treatment of opiate
addiction, rapidly taking over more market share from competition. Upon forming
a joint partnership with medical institutions, CITA will aid in the selection of
a comprehensive promotion plan that will raise the consciousness of the public
sector in an educational fashion, as well as inform about CITA, adding value to
medical institution's name and image.
New Subsidiary
The Company has recently formed a wholly owned subsidiary, incorporated
in the state of Delaware that has no activity at this time.
ITEM 2. DESCRIPTION OF PROPERTY
The Company leases office suite services at 9025 Wilshire Blvd. Suite
301, Beverly Hills, CA 90211. The majority of the company's employees occupy
space in the facilities where detoxification procedures are performed. Other
employees have small office spaces in their region or telecommute. The company
also has an office at 51 E. Campbell Ave. Suite 101-D, Campbell, CA.
ITEM 3. LEGAL PROCEEDINGS
No material legal proceedings, to which the Company is a party or to
which the property of the Company is subject, are pending or are known by the
Company to be threatened.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
There were no meetings of the shareholders in the fourth quarter of
1999.
<PAGE>
PART II
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company's Common Stock has been listed for quotation in the
Electronic Bulletin Board maintained by the National Association of Securities
Dealers, Inc. trading under the symbol "DTOX".
The number of record holders of Common Stock as of December 31, 1999 was
approximately 767 including nominees of beneficial owners.
Holders of Common Stock are entitled to receive such dividends as may
be declared by the Company's Board of Directors. No dividends on the Common
Stock have been paid by the Company to date nor does the Company anticipate that
dividends will be paid in the foreseeable future.
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Through 1997, the Company was an inactive corporation. At a meeting of
the shareholders in December 1997, Mr. Joseph Dunn and Mr. Michael Hinton were
elected to the Board of Directors with instructions to reorganize the Company,
complete necessary filings required by applicable law, and to seek one or more
potential businesses to acquire. Mr. Dunn was elected Chairman and CEO of the
Company, and Mr. Hinton was elected as Secretary of the Company.
Acquisition
In August 1998, the Company acquired all of the outstanding shares of
common stock of CITA Americas, Inc. from Aviation Industries, Inc. in exchange
for the issuance of the Company's non-voting convertible preferred stock having
a liquidation value of $2,200,000. In November 1998, the Company changed its
name from Southwestern Environmental Corp. to CITA Biomedical, Inc.
CITA Americas, Inc. is in the business of investigating and treating
addictions to opiates. CITA Americas, Inc. holds certain rights to the Ultra
Rapid Opiate Detoxification ("UROD"), a non-invasive medical procedure
administered under local anesthesia to detoxify patients addicted to opiates
such as heroin, methadone, morphine, percodan, percocet, darvon and other
narcotics. The procedure is performed over a four to seven hour period following
which the patient has only residual opiates in his or her system. The patient
then is required to undergo an intense psychotherapy recovery program. The
Company generally charges a fee of $7,000 per UROD treatment.
<PAGE>
In light of the fact that the Company was essentially inactive through
August 1998, and is considered in a development stage through 1999, period to
period comparisons of financial results are not meaningful. Nevertheless, the
following information is provided.
Revenue
The Company's revenues for 1999 were $505,455 compared to revenues of
$173,384 in 1998. Essentially all of this revenue was derived from procedures
performed by CITA Americas, Inc.
Cost of Revenues
The Company's cost of revenues in 1999 was $283,627. This resulted in a
gross profit of $221,828 or a gross profit margin of 45%. Compared to $77,580
cost of revenues in 1998, resulting in a gross profit of $95,804, or a gross
profit margin of 55.3%. This decrease in gross profit margin was due to the
overhead cost of expanding from 2 facilities in 1998 to 5 facilities in 1999.
<PAGE>
Other Expenses
General and administrative expenses in 1999 were $816,488 compared to
$317,515 in 1998. In addition, in 1999 the Company incurred depreciation and
amortization expenses of $120,557 compared to $87,509 in 1998. This resulted in
total operating expenses of $1,220,672 and on operating loss of $715,000
compared to $2,768,060 and an operating loss of $2,594,676 in 1998 compared to a
net operating loss of $17,623 in 1997.
Capital Resources
During 1999, the Company received advances from it offices in the
amount of $129,290 in addition to advances from a non- related party in the
amount of $321,929. The Company had no other financing activities in 1999.
The Company is engaged in no other material financing transactions in
1998. The Company anticipates financing its operations from net cash flow from
operations and third party financing transactions. The Company intends to
explore all options available to it with respect to such potential financing.
The Company's newly formed subsidiary does intend to raise capital in
2000 but will do so directly through the subsidiary and not through the parent
CITA Biomedical, Inc.
Effect of Inflation
Inflation did not have a significant effect on the operations of the
Company in 1999, nor is it expected to have any significant effect on operations
in the near future.
ITEM 7. FINANCIAL STATEMENTS
See index beginning on page F-l.
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING DISCLOSURE
There were no disagreements with the Company's accountants on any
matter of accounting principles or practices, financial statement disclosure or
auditing scope or procedure for the 1999 fiscal year.
<PAGE>
PART III
ITEM 9. DIRECTORS AND EXECUTIVE OFFICERS
Name AGE Position
- ---- --- --------
Joseph Dunn 49 Chairman, CEO, President, CFO
Michael C. Hinton 53 Secretary, Director
Joseph Dunn has served as an officer and director of the Company since
December 15, 1998. Since 1994 he has been CEO of AVT, a firm engaged in the
business of electronic operator and long distance services and Executive Vice
President of Kane Gray, Inc. a firm engaged in the business of providing traffic
management services to major corporations. Prior thereto and from 1980 he was
Chief Executive Officer of Azonic Technology, Inc. that was engaged in the
design, manufacture, sale and distribution of devices used in the etching and
cleaning of silicon wafers. Mr. Dunn has also served as interim president and
director of various technology firms that needed to undergo restructuring and
market turnaround. Mr. Dunn graduated from Falls College in Atlanta, Georgia in
1970 with a degree in data processing and has taken courses in business at the
University of California in Hayward, California and the UCLA Graduate School of
Management in Los Angeles, California.
Mr. Hinton has been an officer and director of the Company since
December 15, 1997. Since 1990 he has been engaged in managing his own
investments and is the sole owner of Multimarket Americas Export Corp., which is
engaged in exporting telephone and construction equipment and the import of food
products. Mr. Hinton received a bachelor's degree in economics from Colorado
State University.
ITEM 10. EXECUTIVE COMPENSATION
The Company did not compensate its officers with stock or salary for
fiscal year ending December 1999 however; it does anticipate compensation of
both in 2000.
The Company has adopted a stock option plan but has no retirement,
pension, or profit sharing, for the benefit of its officers, directors or other
employees, but the Board of Directors may recommend one or more such programs
for adoption in the future. The company does have insurance and 401k plan
offered through it subsidiary CITA Americas, Inc.
Employment Contracts
As of December 1999, the Company had no employment agreements with any
of its executive officers or directors and all executive officers presently
serve without compensation. Each of the Company's officers serves at the
pleasure of the Board of Directors. However, the Company may execute employment
agreements with its executive officers or other employees or consultants in the
future, depending on results of operations.
<PAGE>
No officer is entitled to receive any additional compensation for his
services to the Company as a director.
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
At December 31, 1999, the Company had outstanding 7,766,662 shares of
Common Stock the only class of voting securities outstanding. Each share of
Common Stock entitles the holder to one vote in any matter submitted to
shareholders for approval.
The following tabulates holdings of Common Stock of the Company by each
person who holds of record or is known by management of the Company to own
beneficially more than 5 % of the voting securities outstanding as of December
31, 1999, and, in addition, by all directors and officers of the Company
individually and as a group. To the knowledge of management, the shareholders
listed below have sole voting and investment power, except as otherwise noted.
Number
of Shares Percent
Name and Address Securities of Voting
- ---------------- ---------- ---------
Joseph Dunn 2,400,000 30.9%
Michael Hinton 200,000 2.6%
All Directors and Officers 2,600,000 33.5%
as a group (two persons)
The Company knows of no arrangement, including the pledge by any person
of securities of the Company, which may at a subsequent date result in a change
of control of the Company.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
None
<PAGE>
PART IV
ITEM 13. EXHIBITS, FINANCIAL STATEMENTS SCHEDULES AND REPORTS ON
FORM 8-K
(a) Financial Statements and Schedules. See Index to
Financial Statements beginning on page F- 1.
(B) Exhibit . The following exhibits are filed with or incorporated by
reference into this report:
Exhibit Description
2.3 Closing Agreement between Equine Enterprises, Inc., and the Company,
dated March 10, 1987
3.1 Amended and Restated Articles of Incorporation filed January 14, 1982
with the Secretary of State of the State of Colorado.
3.2 Amended and Second Restated Articles of Incorporation filed
January 3,1983 with the Secretary of State of the State of Colorado.
3.3 Amended and Second Restated Articles of Incorporation filed July
28, 1993, with the Secretary of State of the State of Colorado.
3.4 Bylaws adopted by the Company effective June 9, 1981
4.1 Specimen certificate for Common Shares, par value $.01 per share.
10.1 Agreement between Company and Mr. Gary E. Keogh.
10.2 1993 Stock Option Plan.
Incorporated by reference to the Company Form 8-K dated March 20, 1987.
Incorporated by reference to the Company's Registration Statement No. 2-81022D
on Form S-18 dated December 21, 1992.
Incorporated by reference to the like-numbered exhibits filed with the
Company's Form 8-K dated July 7, 1993.
Incorporated by reference to the like-numbered exhibits filed with the
Company's Form 8-K dated August 6, 1993.
Incorporated by reference to the like-numbered exhibits filed with the
Company's report on Form 10-KSB for the fiscal year ended September 30,
1993.
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
CITA BIOMEDICAL, INC.
By: /s/ Joseph Dunn
-----------------
Joseph Dunn
Chairman of the Board
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the Registrant in the capacities and on the dates indicated.
DATE SIGNATURE TITLE
April , 2000 /s/ Joseph Dunn Chairman of the Board,
--------------------- Chief Executive Officer,
Joseph Dunn President and Chief
Financial Officer
(Principal Executive Officer)
April , 2000 /s/ Michael C, Hinton Director
----------------------
Michael C. Hinton
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
Page
----
Independent auditors' report...............................................F-2
Consolidated balance sheet as of December 31, 1999.........................F-3
Consolidated statements of operations, for the years ended
December 31, 1999 and 1998 and for the period August 12, 1998
(beginning of development stage) through December 31, 1999...............F-4
Consolidated statements of shareholders' equity (deficit) for the
two year period ending December 31, 1999.................................F-5
Consolidated statements of cash flows, for the years ended
December 31, 1999 and 1998 and for the period August 12, 1998
(beginning of development stage) through December 31, 1999...............F-6
Notes to consolidated financial statements.................................F-7
F-1
<PAGE>
To the Board of Directors and Shareholders
CITA Biomedical, Inc
INDEPENDENT AUDITORS' REPORT
We have audited the accompanying consolidated balance sheet of CITA Biomedical,
Inc. (a Colorado corporation in the development stage) as of December 31, 1999
and the related consolidated statements of operations, shareholders' equity
(deficit) and cash flows for the years ended December 31, 1999 and 1998. These
consolidated financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the consolidated financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of CITA Biomedical,
Inc., as of December 31, 1999 and the results of their operations and cash flows
for the years ended December 31, 1999 and 1998, in conformity with generally
accepted accounting principles.
The accompanying consolidated financial statements have been prepared assuming
the Company will continue as a going concern. As shown in the accompanying
consolidated financial statements, the Company has a working capital deficit,
negative cash flows from operations and has a limited operating history. These
and other factors discussed in Note A to the consolidated financial statements
raise a substantial doubt about the ability of the Company to continue as a
going concern. Management's plans in regard to those matters are also described
in Note A. The Company's ability to achieve its plans with regard to those
matters, which may be necessary to permit the realization of assets and
satisfaction of liabilities in the ordinary course of business, is uncertain.
The consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.
Cordovano and Harvey, P.C.
Denver, Colorado
April 12, 2000
F-2
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
CONSOLIDATED BALANCE SHEET
December 31, 1999
ASSETS
<TABLE>
<CAPTION>
<S> <C>
CURRENT ASSETS
Cash...............................................................................$ -
Receivables, other ................................................................ -
---------
TOTAL CURRENT ASSETS -
PROPERTY AND EQUIPMENT, net of
accumulated depreciation of $31,357 (Note C)...................................... 21,043
INTANGIBLE ASSETS, net of
accumulated amortization of $188,134 (Note A)..................................... 936,766
DEPOSITS................................................................................. 13,577
---------
$ 971,386
=========
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable, trade............................................................$ 162,709
Accrued expenses................................................................... 289,628
Accrued salaries................................................................... 28,567
Advances payable................................................................... 321,929
Advances payable to officer (Note B)............................................... 129,290
Due to related party (Note B)...................................................... 68,000
---------
TOTAL CURRENT LIABILITIES 1,000,123
---------
COMMITMENTS (Note H)..................................................................... -
SHAREHOLDERS' EQUITY (DEFICIT)
Preferred stock, stated at fair value, 30,000,000 shares authorized;
1,000 shares issued and outstanding............................................. 896,444
Common stock, $.01 par value; 150,000,000 shares authorized;
7,766,662 shares issued and outstanding ......................................... 77,667
Additional paid in capital.........................................................3,772,475
Accumulated deficit...............................................................(3,801,072)
Deficit accumulated during development stage....................................... (974,251)
---------
TOTAL SHAREHOLDERS' EQUITY (DEFICIT) (28,737)
---------
$ 971,386
=========
</TABLE>
See accompanying notes to the consolidated financial statements.
F-3
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
For the Years Ended December 31, August 12, 1998
------------------------------------- Through
1999 1998 December 31, 1999
---------- ----------- -----------------
<S> <C> <C> <C>
REVENUES.................................................................. $ 505,455 $ 172,634 $ 678,089
OPERATING EXPENSES
Cost of revenues................................................... 283,627 76,809 360,436
General and administrative......................................... 816,488 317,536 1,105,024
Depreciation and amortization...................................... 120,557 44,220 164,777
---------- ----------- -----------
TOTAL OPERATING EXPENSES 1,220,672 438,565 1,630,237
---------- ----------- -----------
OPERATING LOSS (715,217) (265,931) (952,148)
NON-OPERATING INCOME (EXPENSE)
Interest expense................................................... (23,077) (7,551) (23,077)
Interest income.................................................... 653 321 974
---------- ----------- -----------
NET LOSS BEFORE INCOME TAXES (737,641) (273,161) (974,251)
INCOME TAXES (NOTE F)..................................................... - - -
---------- ----------- -----------
NET LOSS $ (737,641) $ (273,161) $ (974,251)
========== =========== ===========
NET LOSS PER COMMON SHARE:
Basic and diluted.................................................. $.(0.09) $.(0.11)
========== ===========
SHARES USED FOR COMPUTING NET LOSS PER SHARE:
Basic and diluted.................................................. 7,766,662 2,404,162
========== ===========
</TABLE>
See accompanying notes to the consolidated financial statements.
F-4
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
From January 1, 1997 through December 31, 1999
<TABLE>
<CAPTION>
Preferred Stock Common Stock Additional Total
-------------------- ------------------- Paid-in Accumulated Shareholders'
Shares Amount Shares Amount Capital Deficit Equity
------- --------- --------- ------- ----------- ------------- -------------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance, January 1, 1997*....................... - $ - 266,662 $ 2,667 $ 3,506,037 $ (3,734,211) $ (225,507)
Net loss for the year ended
December 31, 1997............................. - - - - - (30,310) (30,310)
------ -------- --------- ------- ----------- ------------ ----------
BALANCE, December 31, 1997 - - 266,662 2,667 3,506,037 (3,764,521) (255,817)
Shares issued for conversion of debt
(Note B)...................................... - - 4,200,000 42,000 157,038 - 199,038
Shares issued, recorded at fair value,
liquidation value of $2,200,000
for acquisition of CITA Americas (Note A)..... 1,000 896,444 - - - - 896,444
Shares valued at fair value of common stock
on date of issuance for acquisition costs
of CITA Americas (Note A)..................... - - 2,200,000 22,000 81,400 - 103,400
Shares issued for payment of compensation
and accounts payable (Note B)................. - - 1,100,000 11,000 28,000 - 39,000
Net loss for the year ended December 31, 1998... - - - - - (273,161) (273,161)
------ -------- --------- ------- ----------- ------------ ----------
BALANCE, December 31, 1998 1,000 $ 896,444 7,766,662 $ 77,667 $ 3,772,475 $ (4,037,682) $ 708,904
Net loss for the year ended December 31, 1999... - - - - - (737,641) (737,641)
------ -------- --------- ------- ----------- ------------ ----------
BALANCE, December 31, 1999 1,000 $ 896,444 7,766,662 $ 77,667 $ 3,772,475 $ (4,775,323) $ (28,737)
====== ======== ========= ======= =========== ============ ==========
</TABLE>
F-5
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For the Years Ended December 31, August 12, 1998
------------------------------- Through
1999 1998 December 31, 1999
------------ ------------ -----------------
<S> <C> <C> <C>
OPERATING ACTIVITIES
Net loss............................................................. $ (737,641) $ (273,161) $ (974,251)
Transactions not requiring cash:
Depreciation and amortization.................................... 120,557 44,220 164,777
Changes in current assets and current liabilities:
Decrease in receivables and prepaid expenses.................... 30,250 - 30,250
Decrease in receivables and prepaid expenses;
net of $41,728 from purchase of CITA Americas, Inc............ - 11,478 11,478
Increase in accounts payable and accrued liabilities............. 125,222 - 88,671
Increase in accounts payable and accrued liabilities
net of $88,038 of payables satisfied with common stock and
net of $224,532 effects from purchase of CITA Americas, Inc.... - 181,371 181,371
---------- ----------- ----------
NET CASH USED IN
OPERATING ACTIVITIES.... (461,612) (36,092) (497,704)
---------- ----------- ----------
INVESTING ACTIVITIES
Cash paid for deposits............................................... (581) - (581)
Purchase of CITA Americas, Inc, cash received....................... - 47,066 47,066
---------- ----------- ----------
NET CASH PROVIDED BY
INVESTING ACTIVITIES.... (581) 47,066 46,485
---------- ----------- ----------
FINANCING ACTIVITIES
Advances from officers............................................... 129,290 - 129,290
Advances from unrelated third party 321,929 - 321,929
---------- ----------- ----------
NET CASH PROVIDED BY
FINANCING ACTIVITIES 451,219 - 451,219
NET CHANGE IN CASH AND CASH EQUIVALENTS.................................. (10,974) 10,974 (0)
Cash and cash equivalents, beginning...................................... 10,974 - -
---------- ----------- ----------
Cash and cash equivalents, ending......................................... $ (0) $ 10,974 $ (0)
========== =========== ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest.................................................... $ - $ - $ -
========== =========== ==========
Cash paid for income taxes................................................ $ - $ - $ -
========== =========== ==========
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of CITA Americas, Inc in exchange for 1,000 shares of
preferred stock (Note A)............................................. $ - $ 896,444 $ 896,444
========== =========== ==========
Stock issued in satisfaction of note payable (Note B)..................... $ - $ 150,000 $ 150,000
========== =========== ==========
</TABLE>
F-6
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant accounting policies
Organization and business:
CITA Biomedical, Inc. (the "Company") was incorporated in the state of Colorado
on June 9, 1981 under the name of Blue Grass Breeders, Inc. From inception
through February 1983 the Company was involved in raising equity capital. From
February 1983 through March 30, 1991, the Company was engaged in the business of
acquiring, breeding and selling thoroughbreds and quarterhorses, and from
October 1, 1993 through December 15, 1994, the Company was engaged in the
manufacture and sale of computer hardware and software. The Company ceased
operations in both industries due to continued losses and the inability to meet
obligations. From April 1991 through September 1993, and from December 15, 1994
through August 11, 1998 the Company was an inactive shell corporation. During
that period the Company was known as Southwestern Environmental Corp.
On August 12, 1998, the Company purchased all of the outstanding shares of
common stock of CITA Americas, Inc. from Aviation Industries, Inc. pursuant to a
Stock Purchase Agreement entered into in July 1998. The purchase price was paid
through the issuance of non-voting $.10 par value redeemable convertible
preferred stock of the Company. The preferred stock is redeemable for $2,200,000
in cash or may be converted to common stock valued at $2,200,000 as of the date
of conversion. The preferred stock was valued at $896,444, which in management's
opinion approximates the fair value of the preferred stock as of the date of the
acquisition. The president and a director of the Company received 2,000,000 and
200,000 shares, respectively of the Company's restricted common stock, valued at
$103,400 in connection with the acquisition. CITA Americas, Inc., a Nevada
corporation, currently in the development stage, was formed in March of 1998.
CITA Americas was formed to engage in the investigation and treatment of
addiction. In conjunction with the purchase, the Company changed its name from
Southwestern Environmental Corp. to CITA Biomedical, Inc. - See Note G.
Concurrent with the Company's acquisition of CITA Americas, Inc., on August 12,
1998 the Company entered the development stage. Substantially all of the
operations of the Company presented for the years ended December 31, 1999 and
1998 are results of operations of CITA Americas, Inc. As of December 31, 1999,
the Company has not generated significant revenues from operations, nor has it
achieved planned principal operations.
F-7
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant
accounting policies continued
Organization and business continued:
As shown in the accompanying consolidated financial statements, the Company has
a working capital deficit, incurred a net loss of $737,641 for the year ended
December 31, 1999, has negative cash flows from operations and has a limited
operating history. Those factors, as well as the uncertain condition that the
Company faces as a new business, create an uncertainty about the Company's
ability to continue as a going concern.
Management plans to commence significant operations during the next year by
entering into agreements with additional medical facilities that will administer
the Company's treatment method thereby increasing the number of patients
treated. Management also plans to increase the number of patients treated at
current medical facilities. The ability of the Company to continue as a going
concern is dependent on the success of these plans, and ultimately upon
achieving profitability. The financial statements do not include any adjustments
that might be necessary if the Company is unable to continue as a going concern.
Summary of significant accounting policies:
Basis of presentation
The Company's primary operations since August 1998 have been devoted to
developing its addiction treatment business. As a result, the consolidated
financial statements are presented in accordance with Statement of Financial
Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by Development
Stage Enterprises." In order to generate significant revenues and become an
operating business, the Company will need to continue to market its treatment
method, enter into additional agreements with medical facilities that will
administer the Company's treatment method, and increase the number of patients
treated with the Company's drug addiction treatment method.
Principles of consolidation
The Company's consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary CITA Americas, Inc. The consolidated
statement of operations include the activity of the subsidiary from date of
acquisition, August 12, 1998. All material intercompany accounts and
transactions have been eliminated in consolidation.
Use of estimates
The preparation of the financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets, liabilities, and
disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
F-8
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant
accounting policies, continued
Summary of significant accounting policies continued:
Reclassifications
Certain prior-year amounts have been reclassified for comparative purposes to
conform to the current-year presentation.
Cash
The Company considers all short-term, highly liquid investments with an original
maturity date of three months or less to be cash equivalents. At December 31,
1999 the Company did not have any cash equivalents. Cash is stated at cost,
which approximates fair value.
Property and equipment
Property and equipment are stated at cost less accumulated depreciation.
Depreciation is provided using the straight-line method over the estimated
useful lives of the assets, which is estimated to be three years. Expenditures
for repairs and maintenance are charged to expense when incurred. Expenditures
for major renewals and betterments, which extend the useful lives of existing
equipment, are capitalized and depreciated. Upon retirement or disposition of
property and equipment, the cost and related accumulated depreciation are
removed from the accounts and any resulting gain or loss is recognized in the
consolidated statements of operations.
Intangible assets
Intangible assets are stated net of accumulated amortization and include the
rights to the UROD method and the use of the name CITA valued at $1,030,900 and
certain patent pending rights totaling $94,000. The $1,030,900 is amortized on a
straight-line basis over ten years. Amortization expense for the year ended
December 31, 1999 was $103,090 and for the period from August 12, 1998 through
December 31, 1998 was $38,664. Prior to August 12, 1998, amortization expense
was $46,380, and recorded on the separate books of the Company's subsidiary. The
Company has not recorded any amortization expense for the pending patent rights.
Long-lived assets
The Company periodically reviews the values assigned to long-lived assets, such
as property and equipment and intangibles to determine whether any impairments
are other than temporary. Management believes that the long-lived assets in the
accompanying balance sheets are appropriately valued.
F-9
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant
accounting policies continued
Summary of significant accounting policies continued:
Income taxes
Income taxes are provided for the tax effects of transactions reported in the
consolidated financial statements and consist of taxes currently due plus
deferred taxes related primarily to differences between the recorded book basis
and tax basis of assets and liabilities for financial and income tax reporting.
The deferred tax assets and liabilities represent the future tax return
consequences of those differences, which will either be taxable or deductible
when the assets and liabilities are recovered or settled. Deferred taxes are
also recognized for operating losses that are available to offset future taxable
income and tax credits that are available to offset future federal income taxes.
Revenue recognition
The Company recognizes revenue when services are provided.
Stock-based compensation
SFAS No. 123, "Accounting for Stock-Based Compensation" permits the use of
either a fair value based method or the method defined in Accounting Principles
Board Opinion 25, "Accounting for Stock Issued to Employees" ("APB 25") to
account for stock-based compensation arrangements. Companies that elect to use
the method provided in APB 25 are required to disclose pro forma net income and
earnings per share that would have resulted from the use of the fair value based
method. The Company has elected to continue to determine the value of
stock-based compensation arrangements under the provisions of APB 25 and,
accordingly, has included pro forma disclosures under SFAS No. 123 in Note E.
Fair value of financial instruments
SFAS 107, "Disclosure About Fair Value of Financial Instruments," requires
certain disclosures regarding the fair value of financial instruments. The
Company has determined, based on available market information and appropriate
valuation methodologies, the fair value of its financial instruments
approximates carrying value. The carrying amounts of cash, accounts receivable,
prepaid expenses, accounts payable, and other accrued liabilities approximate
fair value due to the short-term maturity of the instruments.
F-10
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant
accounting policies continued
Summary of significant accounting policies continued:
Loss per share
The Company accounts for loss per share in accordance with SFAS No. 128,
"Earnings Per Share" (SFAS 128). Under SFAS 128, net loss per share-basic
excludes dilution and is determined by dividing loss available to common
shareholders by the weighted average number of common shares outstanding during
the period. Net loss per share-diluted reflects the potential dilution that
could occur if securities and other contracts to issue common stock were
exercised or converted into common stock. As of December 31 1999, there were
2,200,000 stock options and 2,200,000 shares, that could be issued if the
Company's preferred stock is converted assuming a conversion rate of $1.00 per
share, that were not included in the calculation of net loss per share-diluted
because they were antidilutive.
Recently issued accounting pronouncements
The Company has adopted the following new accounting pronouncements for the year
ended December 31, 1999. There was no material effect on the consolidated
financial statements presented from the adoption of the new pronouncements.
SFAS No. 130, "Reporting Comprehensive Income," requires the reporting and
display of total comprehensive income and its components in a full set of
general-purpose financial statements.
SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information," is based on the "management" approach for reporting segments. The
management approach designates the internal organization that is used by
management for making operating decisions and assessing performance as the
source of the Company's reportable segments. SFAS No. 131 also requires
disclosure about the Company's products, the geographic areas in which it earns
revenue and holds long-lived assets, and its major customers.
SFAS No. 132, "Employers' Disclosures about Pensions and Other Post-retirement
Benefits," which requires additional disclosures about pension and other
post-retirement benefit plans, but does not change the measurement or
recognition of those plans.
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities." SFAS No. 133 establishes accounting and
reporting standards for derivative instruments, including derivative instruments
embedded in other contracts, and for hedging activities. SFAS No. 133 requires
an entity to recognize all derivatives as either an asset or liability and
measure those instruments at fair value, as well as identify the conditions for
which a derivative may be specifically designed as a hedge. SFAS No. 133 is
effective for all fiscal quarters of fiscal years beginning after June 15, 1999.
F-11
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note A: Organization and business and summary of significant
accounting policies continued
Summary of significant accounting policies continued:
Recently issued accounting pronouncements, continued
This statement is not expected to affect the Company as the Company currently
does not have any derivative instruments or hedging activities.
In June 1999, the FASB issued SFAS No. 137, which amended the implementation
date for SFAS No. 133 to be effective for all fiscal quarters of all fiscal
years beginning after June 15, 2000.
Statement of Position ("SOP") 98-1, "Accounting for the Costs of Computer
Software Developed or Obtained for Internal Use." This SOP requires that
entities capitalize certain internal-use software costs once certain criteria
are met.
SOP 98-5, "Reporting on the Costs of Start-Up Activities." SOP 98-5 provides,
among other things, guidance on the reporting of start-up costs and organization
costs. It requires costs of start-up activities and organization costs to be
expensed as incurred.
The Company will continue to review these new accounting pronouncements over
time, in particular SFAS 131 and SOP 98-1, to determine if any additional
disclosures are necessary based on evolving circumstances.
Note B: Related party transactions
During the year ended December 31, 1998, the Company issued 2,000,000 and
200,000 shares of its restricted common stock, valued at $103,400 to the
President and Secretary of the Company, respectively, for payment of finders'
fees related to the acquisition of CITA Americas, Inc. The restricted common
stock was valued based on the conversion rate ($.047 per share) of the Tanaka
Capital Limited note as described below. The $103,400 has been recorded as part
of the purchase price.
The Board of Directors voted to compensate the President and Secretary $2,000
per month each, commencing December 15, 1997 through the month in which the
Company closed on an acquisition. The Company closed on its acquisition of CITA
Americas, Inc. on August 12, 1998, therefore total accrued compensation expense
totaled $16,000 each. The amounts due to the officers at August 12, 1998 were
satisfied by the issuance of 200,000 shares of the Company's restricted common
stock to each of the officers.
F-12
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note B: Related party transactions, continued
During 1998, an affiliate of the Company acquired the Company's seven percent
$150,000 note payable and accrued interest of $49,038 to Tanaka Capital Limited.
Once the note was acquired by the affiliate, the Company converted the note to
4,200,000 shares of the Company's unrestricted common stock. The shares were
issued in two certificates of 2,100,000 shares each to corporations owned or
controlled by affiliates of the Company. One certificate was issued on August 4,
1998 and the other on October 8, 1998. Both certificates were issued on a
"post-split" basis. See Note D - Shareholders' equity.
The terms of the promissory note included certain terms for conversion, such as
the conversion being subject to the stock becoming available pursuant to a vote
of the current shareholders to increase the capitalization of the Company.
Further, the conversion was to be based on the average of certain market
quotations five days prior to the date of conversion discounted by 60 percent.
To negotiate the conversion of the note, dated June 21, 1994, which was due and
payable on June 21, 1995, management agreed to convert the note at approximately
$.047 per share. The Company's common stock had been thinly traded and the
market prices during the period of negotiations were in management's opinion,
negligible and not representative of a market value. The promissory note was
originally issued as payment for the Company's repurchase of 1,000,000 shares of
the Company's common stock that had been sold to Tanaka Capital Limited for
$50,000.
On September 20, 1998, the Company issued 200,000 shares of common stock to a
previous officer of the Company, who consulted with the Company on
reorganization and restructuring. The transaction was recorded at the cost of
the services which was $2,000. The services had been rendered in prior periods
and the issuance of the common stock satisfied the $2,000 obligation to the
former officer.
On September 20, 1998, the Company issued 500,000 shares of common stock to an
affiliate who consulted with the Company on reorganization, restructuring, and
acquisition strategies and provided investment-banking services. These services
were rendered in prior periods and totaled $5,000. The issuance of the stock was
considered payment for the $5,000 obligation due to the affiliate. The affiliate
also was party to the transaction regarding the conversion of the Tanaka Capital
Limited note as described above.
During the year ended December 31, 1999 an officer and director of the Company
advanced the Company approximately $129,290 for working capital purposes. The
amount due to the officer is included in the accompanying consolidated financial
statements as advances payable to officer.
F-13
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note B: Related party transactions, continued
CITA Americas, Inc.
CITA Americas, Inc. was formed by Aviation Industries, Inc. ("Aviation") in
March of 1998. Aviation acquired from CITA Americas, Inc., a Delaware
corporation ("CITA-Delaware"), certain rights, copyrights, trademarks and
pending patent rights related to the addiction treatment method known as UROD.
Aviation valued the transaction at approximately $1,057,500. When CITA Americas
was formed, Aviation transferred the rights obtained from CITA-Delaware to the
newly-formed CITA Americas, Inc. From time to time Aviation would advance monies
to CITA Americas for working capital purposes. Amounts due to Aviation for these
advances total $68,000 and is included in the accompanying consolidated
financial statements as due to related party.
Note C: Property and equipment
Furniture and equipment consisted of office furniture and equipment including
computers and credit card machines totaling $52,400. Accumulated depreciation at
December 31, 1999 totaled $31,537. Depreciation expense for the years ended
December 31, 1999 and 1998 totaled $17,467 and $5,556, respectively.
Note D: Shareholders' equity
Preferred Stock
The Company is authorized to issue thirty million shares of $1.00 par value
preferred stock, which may be issued in series with such designations,
preferences, stated values, rights, qualifications or limitations as determined
by the Board of Directors.
During the year ended December 31, 1998, the Company issued 1,000 shares of its
convertible preferred stock with a liquidation value of $2,200 per share in
exchange for all of the outstanding common stock of CITA Americas, Inc. The
preferred stock is convertible into the Company's common stock within one year
of the issuance date of August 12, 1998. As of December 31, 1999 the shares were
not converted, however the Company is contemplating conversion in 2000.
Common Stock
On December 15, 1997 the shareholders approved a reverse split of the
outstanding shares of common stock, one existing share for up to twenty shares
of the Company. The reverse split was effective August 14, 1998, whereby one
share was exchanged for every fifteen shares outstanding. As of the date of the
reverse split the Company had 3,999,929 shares outstanding that were exchanged
for 266,662 shares. There was no change in either the par value or the number of
authorized common shares of the Company. The accompanying consolidated financial
statements have been retroactively restated to give effect to the reverse split.
F-14
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note E: Stock based compensation
Common stock options
On June 29, 1998 the two members of the board of directors granted options to
the president and secretary of the Company for 2,000,000 and 200,000 shares of
its common stock, respectively, exercisable for $.275 per share. The options are
fully vested and expire on June 29, 2003. The options were granted at 110
percent of the market value of the Company's common stock as of the date of
grant. In accordance with APB 25, no compensation expense was recorded.
Summary
A summary of the status of the Company's stock option awards as of December 31,
1999, and the changes during the year ended December 31, 1999 is presented
below:
Fixed Options Number
--------------------------------------------------------
Outstanding at January 1, 1999............. 2,200,000
Granted.................................... -
Exercised.................................. -
Canceled................................... -
---------
Outstanding at December 31, 1999........... 2,200,000
=========
The weighted average exercise price per share for the 2,200,000 outstanding
options at December 31, 1999 was $.275.
SFAS 123
In October 1995, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards No. 123 (SFAS 123), "Accounting form Stock-Based
Compensation". SFAS 123 encourages the use of a fair value based method of
accounting for compensation expense associated with stock option awards and
similar plans. SFAS 123 permits the continued use of the intrinsic value based
method prescribed by APB 25, but requires additional disclosures, including pro
forma calculations of net earnings and earnings per share, as if the fair value
method of accounting prescribed by SFAS 123 had been applied for the applicable
periods.
The fair value of each option granted has been estimated as of the grant date
using the Black-Scholes option-pricing model with the following weighted-average
assumptions: risk-free interest rate of 5.63 percent, expected volatility of 80
percent, expected life of five years, and no expected dividends. During the year
ended December 31, 1998, the weighted-average fair values of options granted was
$.12 for options granted with an exercise price greater than the market price of
the stock. There were no options granted with an exercise price less than or
equal to the market price of the stock.
F-15
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note E: Stock based compensation, continued
SFAS 123, continued
Had compensation expense been determined based on the fair value at the grant
date, and charged to expense over vesting periods, consistent with the
provisions of SFAS 123, the Company's net loss and net loss per share would have
increased to the pro forma amounts indicated below:
Amount
---------------
As reported at December 31, 1998:
Net loss................................. $ (273,161)
Net loss per share - basic and diluted... $ (0.11)
Pro Forma:
Net loss................................. $ (537,161)
Net loss per share - basic and diluted... $ (0.22)
The Black-Scholes option valuation model was developed for use in estimating the
fair value of traded options, which have no vesting restrictions and are fully
transferable. Option valuation models also require the input of highly
subjective assumptions such as expected option life and expected stock price
volatility. Because the Company's stock-based awards have characteristics
significantly different from those of traded options and because changes in the
subjective input assumptions can materially affect the fair value estimate, the
Company believes that the existing option valuation models do not necessarily
provide a reliable single measure of the fair value of its stock-based awards.
F-16
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note F: Income taxes
A reconciliation of the U.S. statutory federal income tax rate to the effective
tax rate follows for the years ended December 31, 1999 and 1998:
December 31,
-----------------------
1999 1998
---------- ---------
U.S. statutory federal rate................ 34.00% 32.55%
State income tax rate,
net of federal benefit.................. 4.25% 4.25%
Temporary differences...................... (.95)% (.88)%
Net operating loss for which no tax
Benefit is currently available........... (37.30) (35.92%)
---------- ---------
- % -%
========== =========
At December 31, 1999 and 1998, deferred taxes consisted of the following:
December 31,
-------------------------
1999 1998
----------- ---------
Deferred tax assets,
Net operating loss.................. $ 373,254 $ 98,114
Valuation allowance.................... (373,254) (98,114)
----------- ---------
Net deferred taxes............... $ -0- $ -0-
=========== =========
The valuation allowance offsets the net deferred tax asset for which there is no
assurance of recovery. The change in the valuation allowance for the years ended
December 31, 1999 and 1998 totaled $275,140 and $98,114, respectively, which
approximated the current tax benefit for each year. The net operating loss
carryforward expires through the year 2018. The valuation allowance will be
evaluated at the end of each year, considering positive and negative evidence
about whether the deferred tax asset will be realized. At that time, the
allowance will either be increased or reduced; reduction could result in the
complete elimination of the allowance if positive evidence indicates that the
value of the deferred tax assets is no longer impaired and the allowance is no
longer required.
Should the Company undergo an ownership change as defined in Section 382 of the
Internal Revenue Code, the Company's tax net operating loss carryforwards
generated prior to the ownership change will be subject to an annual limitation,
which could reduce or defer the utilization of these losses.
F-17
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note G: Acquisition of CITA Americas, Inc.
On August 12, 1998 the Company purchased all of the outstanding common stock of
CITA Americas, Inc. in exchange for 1,000 shares of the Company's preferred
stock valued at management's estimate of fair value of $896,444 with a
liquidation value of the preferred stock of $2,200,000. Net assets of CITA
Americas, Inc. as of the date of the acquisition totaled $896,444, which
approximated fair value. The excess of the purchase price over the fair value of
the assets, in the amount of $103,400 was allocated to the intangible assets
acquired. Amortization expense of $3,879 has been recorded in the accompanying
consolidated financial statements for the year ended December 31, 1998 for the
amortization of the excess of the purchase price over the fair value of the
assets acquired.
The Company has recorded the transaction as a purchase in accordance with
Accounting Principles Board Opinion No. 16. The accompanying consolidated
financial statements include the results of operations of CITA Americas, Inc.
from the date of the acquisition, August 12, 1998 through December 31, 1998.
The following unaudited pro forma condensed consolidated statement of operations
gives effect to the acquisition of CITA Americas, Inc. as if it had occurred at
the beginning of the period presented. The unaudited pro forma condensed
consolidated statement of operations are not necessarily indicative of results
of operations had the acquisition occurred at the beginning of the periods
presented nor of results to be expected in the future.
PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
For the year ended December 31, 1998 (Unaudited)
<TABLE>
<CAPTION>
CITA CITA Pro forma
Biomedical Americas Adjustments Consolidated
----------- ---------- ----------- ------------
<S> <C> <C> <C>
Revenues............................................ $ 172,634 $ 362,946 $ 535,580
Operating expenses.................................. (438,565) (444,002) (6,462) (889,029)
(Loss) income from operations....................... (265,931) (81,056) (346,987)
Interest expense.................................... (7,551) - (7,551)
Interest income..................................... 321 - 321
Net (loss) income................................... (273,161) (81,056) (354,217)
Net (loss) income per share - basic and diluted..... $ (0.11) NA $ (0.15)
Basic and diluted shares outstanding................ 2,404,162 NA 2,404,162
</TABLE>
Pro forma adjustments
The adjustment of $6,462 is the additional pro forma amortization of the excess
of the purchase price of $103,400. The unaudited pro forma condensed
consolidated financial information does not show any adjustments for a change in
the income tax benefit as the total pro forma consolidated benefit for income
taxes would be offset by any valuation allowance due to any deferred tax asset
derived from net operating losses. The valuation allowance offsets the net
deferred tax asset for which there is no assurance of recovery.
F-18
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note G: Acquisition of CITA Americas, Inc., continued
The following is the balance sheet of CITA Americas as of August 11, 1998 and
the results of operations of CITA Americas, Inc. from March 1998 (inception)
through August 11, 1998.
Cash......................................$ 47,066
Other receivables......................... 41,728
---------
Total current assets 88,794
Deposits.................................. 12,996
Property, net............................. 44,066
Intangibles, net of $46,380............... 975,120
---------
$1,120,976
=========
Accounts payable.......................... $ 2,092
Accrued liabilities....................... 154,440
Due to shareholder........................ 68,000
---------
Total current liabilities 224,532
---------
Common stock.............................. 977,500
Accumulated deficit....................... (81,056)
---------
Total shareholders' equity 896,444
---------
$1,120,976
=========
Revenues..................................$ 362,946
Cost of revenues.......................... (162,950)
General and administrative................ (226,338)
Amortization and depreciation............. (54,714)
---------
Net loss before taxes..................... (81,056)
Income taxes.............................. -
---------
Net loss $ (81,056)
=========
F-19
<PAGE>
CITA BIOMEDICAL, INC.
(A Development Stage Company)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note H: Commitments and contingencies
The Company received working capital advances from certain unrelated third
parties totaling approximately $320,000. The Company anticipates converting the
short-term advances to shares of the Company's convertible preferred stock. The
Company accrued interest expense of approximately $23,000 related to the
advances.
F-20
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
(Replace this text with the legend)
</LEGEND>
<CIK> 0000700890
<NAME> CITA BIOMEDICAL, INC.
<MULTIPLIER> 1
<CURRENCY> US DOLLARS
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> DEC-31-1999
<EXCHANGE-RATE> 1
<CASH> 0
<SECURITIES> 0
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 0
<PP&E> 52,400
<DEPRECIATION> 31,357
<TOTAL-ASSETS> 971,386
<CURRENT-LIABILITIES> 1,000,123
<BONDS> 0
0
896,444
<COMMON> 77,667
<OTHER-SE> (1,002,848)
<TOTAL-LIABILITY-AND-EQUITY> 971,386
<SALES> 505,455
<TOTAL-REVENUES> 505,455
<CGS> 283,627
<TOTAL-COSTS> 1,220,672
<OTHER-EXPENSES> (653)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 23,077
<INCOME-PRETAX> (737,641)
<INCOME-TAX> 0
<INCOME-CONTINUING> (737,641)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (737,641)
<EPS-BASIC> (.09)
<EPS-DILUTED> (.09)
</TABLE>
